NEW YORK, September 25, 2017 /PRNewswire/ --
If you want a Stock Review on ACRX, GNMK, VRAY, or NVRO then come overto http://dailystocktracker.com/register/ and sign up for your free customized report. Today, DailyStockTracker.com focuses on the Medical Appliances and Equipment industry, which primarily offers equipment and devices that are designed for diagnosis,
Last Friday, Redwood City, California headquartered AcelRx Pharmaceuticals Inc.'s stock jumped 4.69%, to close the day at $3.35. A total volume of 819,858 shares was traded. The Company's shares have advanced 11.67% in the last month, 55.81% in the previous three months, and 28.85% on an YTD basis. The stock is trading 7.01% above its 50-day moving average and 18.44% above its 200-day moving average. Additionally, shares of AcelRx Pharma, which focuses on the development and commercialization of therapies for the treatment of acute pain, have a Relative Strength Index (RSI) of 55.15.
On September 06th, 2017, AcelRx Pharma announced that Vincent J. Angotti, CEO, will be presenting at the Cantor Fitzgerald Global Healthcare Conference on September 27th, 2017, at 9:45 a.m. ET at the InterContinental New York Barclay Hotel in New York. The presentation will be webcast live and can be accessed under the Investors page of the Company's website. The free research report on ACRX is available at:
Shares in Carlsbad, California headquartered GenMark Diagnostics Inc. saw a slight drop of 0.42%, finishing Friday's session at $9.52. The stock recorded a trading volume of 226,012 shares. The Company's shares have gained 0.32% in the last month. The stock is trading below its 50-day moving average by 8.06%. Furthermore, shares of GenMark Diagnostics, which develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology, have an RSI of 44.19.
On September 18th, 2017, research firm Bank of America/ Merrill initiated a 'Buy' rating on the Company's stock, with a target price of $13 per share. The complimentary report on GNMK can be downloaded at:
Bedford, Ohio headquartered ViewRay Inc.'s stock finished 0.70% lower at $5.65 last Friday at the close. A total volume of 308,893 shares was traded. The Company's shares have advanced 5.02% in the past month and 80.51% on an YTD basis. The stock is trading above its 50-day moving average by 1.98%. Additionally, shares of ViewRay, which designs, manufactures, and markets radiation therapy systems, have an RSI of 50.35.
On September 20th, 2017, ViewRay announced that the Company will hold a meeting for analysts and investors on September 25th, 2017, from 7:00 a.m. to 8:30 a.m. PT during the annual meeting of the American Society for Radiation Oncology (ASTRO) at the Marriott Marquis in San Diego, California. An audio webcast of the presentation will be available under the investor relations section of the Company's website. Visit us today and download our complete research report on VRAY for free at:
Redwood City, California headquartered Nevro Corp.'s shares ended the session 1.67% higher at $87.70. The stock recorded a trading volume of 153,160 shares. The Company's shares have advanced 1.98% in the last month, 18.77% over the previous three months, and 20.70% on an YTD basis. The stock is trading 2.19% above its 50-day moving average and 4.07% above its 200-day moving average. Moreover, shares of Nevro, which focuses on providing products for the patients suffering from chronic pain in the US and internationally, have an RSI of 51.59. Get free access to your technical report on NVRO at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
Subscribe to our Free Newsletters!
Yellow fever is a hemorrhagic fever that is transmitted by infected mosquitoes and it can lead to ...
Routes of drug administration play a major role in a medical treatment. Selecting a right route of ...
Spinal anesthesia and epidural anesthesia are types of regional anesthesia in which when a drug is ...View All